Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama University of California San Diego - La Jolla, La Jolla, California UCSF Benioff Children's Hospital Oakland, Oakland, California Yale-New Haven Hospital, New Haven, Connecticut Winship Cancer Institute of Emory University, Atlanta, Georgia Local Institution - 0034, Chicago, Illinois Local Institution - 0001, Lenexa, Kansas Local Institution - 0024, Boston, Massachusetts Boston Medical Center, Boston, Massachusetts Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia, Pennsylvania Local Institution - 0032, Pittsburgh, Pennsylvania Inova Schar Cancer Institute, Fairfax, Virginia Virginia Commonwealth University (VCU) Medical Center, Richmond, Virginia France
Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, Alsace Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone, Marseille Hôpital Universitaire Necker Enfants Malades, Paris United Kingdom
University Hospitals Sussex NHS Foundation Trust, East Sussex, Brighton And Hove King's College Hospital, London, London, City of Local Institution - 0005, Leeds